WO2013169101A1 - Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate - Google Patents

Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate Download PDF

Info

Publication number
WO2013169101A1
WO2013169101A1 PCT/NL2013/050341 NL2013050341W WO2013169101A1 WO 2013169101 A1 WO2013169101 A1 WO 2013169101A1 NL 2013050341 W NL2013050341 W NL 2013050341W WO 2013169101 A1 WO2013169101 A1 WO 2013169101A1
Authority
WO
WIPO (PCT)
Prior art keywords
granulate
fatty acid
cannabinoid
dosage unit
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2013/050341
Other languages
English (en)
French (fr)
Inventor
Jan Albert De Vries
Maria Vanesa Fernandez Cid
Ana Maria HEREDIA LOPEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Echo Pharmaceuticals BV
Original Assignee
Echo Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201380030415.7A priority Critical patent/CN104363890B/zh
Priority to US14/399,487 priority patent/US20150132400A1/en
Priority to ES13724009.9T priority patent/ES2600465T3/es
Priority to EP13724009.9A priority patent/EP2846768B1/en
Priority to CA2872689A priority patent/CA2872689C/en
Priority to AU2013260246A priority patent/AU2013260246B2/en
Application filed by Echo Pharmaceuticals BV filed Critical Echo Pharmaceuticals BV
Priority to JP2015511392A priority patent/JP2015521175A/ja
Publication of WO2013169101A1 publication Critical patent/WO2013169101A1/en
Anticipated expiration legal-status Critical
Priority to IN9718DEN2014 priority patent/IN2014DN09718A/en
Priority to US15/223,783 priority patent/US9555019B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • 'granulation' in the context of the present invention is understood to be a process that converts a mixture of powders, the particles of which have poor cohesion, into aggregates capable of compaction. Unless indicated otherwise, the term granulation as used herein refers to the process of 'wet granulation'.
  • the fatty acid residue of the sucrose fatty acid mono-ester is selected from lauric, palmitic or stearic acid.
  • Another aspect of the invention relates to oral dosage units containing between 10 wt.% and 98.8 wt% of the granulate according to any of the foregoing.
  • Such dosage units may typically take the form of compressed tablets, capsules containing the granulate, powders, pills, etc. Tablets obtained by direct compression of the granulate of the invention are particularly preferred.
  • Suitable muco-adhesive agents that can be added to the oral dosage units are chosen from the group consisting of carbomers, cellulose derivatives, plant lectin, dextrin, hypromellose, chitosan, polyethylene oxide, alginate and combinations thereof.
  • the oral dosage units comprise up to 3 wt. % of muco- adhesive agents.
  • the granulation method according to the present invention includes wet granulation.
  • wet granulation a binder solution is prepared which is slowly added to a powder under continuous agitation of the mixture. Addition of the binder solution causes aggregation of the powder particles. Following the aggregation step, the solvent of the binder solution is removed using a drying step.
  • the rate of adding the binder solution to the powder, the ratio of binder-solution to powder and the degree of agitation of the wet mass all affect the final particle size distribution of the granules.
  • Tablets were prepared as in example 4 with the only difference that the amphiphilic compound sucrose fatty ester (SML) was substituted by glyceryl monostearate (GMS).
  • SML amphiphilic compound sucrose fatty ester
  • GMS glyceryl monostearate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/NL2013/050341 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate Ceased WO2013169101A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US14/399,487 US20150132400A1 (en) 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
ES13724009.9T ES2600465T3 (es) 2012-05-07 2013-05-03 Granulado que contiene cannabinoide, método para su producción y unidad de dosificación oral que comprende tal granulado
EP13724009.9A EP2846768B1 (en) 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
CA2872689A CA2872689C (en) 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
AU2013260246A AU2013260246B2 (en) 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
CN201380030415.7A CN104363890B (zh) 2012-05-07 2013-05-03 含有大麻素的颗粒物及其制备方法和含有该颗粒物的口服给药单元
JP2015511392A JP2015521175A (ja) 2012-05-07 2013-05-03 カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位
IN9718DEN2014 IN2014DN09718A (https=) 2012-05-07 2014-11-18
US15/223,783 US9555019B2 (en) 2012-05-07 2016-07-29 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167006.1 2012-05-07
EP12167006 2012-05-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/399,487 A-371-Of-International US20150132400A1 (en) 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
US15/223,783 Division US9555019B2 (en) 2012-05-07 2016-07-29 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate

Publications (1)

Publication Number Publication Date
WO2013169101A1 true WO2013169101A1 (en) 2013-11-14

Family

ID=48468727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2013/050341 Ceased WO2013169101A1 (en) 2012-05-07 2013-05-03 Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate

Country Status (9)

Country Link
US (2) US20150132400A1 (https=)
EP (1) EP2846768B1 (https=)
JP (1) JP2015521175A (https=)
CN (1) CN104363890B (https=)
AU (1) AU2013260246B2 (https=)
CA (1) CA2872689C (https=)
ES (1) ES2600465T3 (https=)
IN (1) IN2014DN09718A (https=)
WO (1) WO2013169101A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170165224A1 (en) * 2015-12-09 2017-06-15 Mark KWIECINSKI Compositions for improving safety of pharmacological formulations
WO2017137992A1 (en) * 2016-02-11 2017-08-17 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
JP2017535539A (ja) * 2014-10-21 2017-11-30 ユナイテッド カナビス コーポレイション 大麻抽出物ならびにその調製方法および使用方法
US11241413B2 (en) 2019-04-17 2022-02-08 Nordiccan A/S Cannabinoid lozenge formulation
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
USRE49110E1 (en) 2008-07-16 2022-06-21 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
WO2016205923A1 (en) * 2015-06-25 2016-12-29 Compressed Perforated Puck Technologies Inc. Ingestible plant source pill and method
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
US10542770B2 (en) 2016-03-18 2020-01-28 Aceso Wellness LLC Cannabinoid emulsion product and process for making the same
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
EP3820530A4 (en) * 2018-07-10 2022-03-30 Cardinal Advisory Limited FORMULATION OF CANNABINOID COMPOUNDS
EP3823598A2 (en) * 2018-07-18 2021-05-26 Glatt Gmbh Immediate release formulations of cannabinoids
US11254633B2 (en) 2018-10-05 2022-02-22 Jonas Alcirdas Navickas Cannabis thin layer decarboxylation
WO2020183436A1 (en) * 2019-03-13 2020-09-17 One World Cannabis Ltd. Dosage forms for oral delivery of cannabinoids, method of preparation and uses of same
DE102019211195A1 (de) * 2019-07-26 2021-01-28 Add Advanced Drug Delivery Technologies Ltd. Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats
EP3946262B1 (en) * 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
CN111202767A (zh) * 2019-09-04 2020-05-29 汉义生物科技（北京）有限公司 大麻全草提取物在改善tau蛋白和β-淀粉样蛋白病理损伤中应用
EP4181916A4 (en) 2020-07-17 2024-12-18 Canna-Chemistries LLC Solid delta9-tetrahydrocannabinol (delta9-thc) compositions
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
IT202000027408A1 (it) * 2020-11-16 2022-05-16 Indena Spa Dispersioni solide di cannabidiolo
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
IL317376A (en) 2022-06-06 2025-02-01 Cannbiorex Pharma Ltd Formulations and compositions for oral administration containing fat-soluble active ingredients
JP7360526B1 (ja) 2022-10-21 2023-10-12 第一工業製薬株式会社 組成物
JP7469550B1 (ja) * 2022-10-21 2024-04-16 第一工業製薬株式会社 固体組成物及びその製造方法
WO2025032115A1 (en) * 2023-08-08 2025-02-13 Avextra Portugal Sa Cannabinoid granule composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064109A2 (en) 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
WO2005004848A1 (en) 2003-07-09 2005-01-20 Chong Kun Dang Pharmaceutical Corp. The solid dispersion of tacrolimus
DE10341264A1 (de) * 2003-09-04 2005-03-24 Grünenthal GmbH Schmelzformulierte, multipartikuläre orale Darreichungsform
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061427B1 (en) * 2006-09-15 2011-07-20 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and an emulsifier and method for its manufacture

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064109A2 (en) 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
WO2005004848A1 (en) 2003-07-09 2005-01-20 Chong Kun Dang Pharmaceutical Corp. The solid dispersion of tacrolimus
DE10341264A1 (de) * 2003-09-04 2005-03-24 Grünenthal GmbH Schmelzformulierte, multipartikuläre orale Darreichungsform
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H.G. BRITTAIN, PHARMACEUTICAL TECHNOLOGY, December 2002 (2002-12-01), pages 56 - 64
HENG PAUL WAN SIA ET AL: "Investigation of melt agglomeration process with a hydrophobic binder in combination with sucrose stearate.", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 19, no. 5, August 2003 (2003-08-01), pages 381 - 393, XP002684440, ISSN: 0928-0987 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49110E1 (en) 2008-07-16 2022-06-21 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
USRE49302E1 (en) 2008-07-16 2022-11-15 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
JP2021042233A (ja) * 2014-10-21 2021-03-18 ユナイテッド カナビス コーポレイション 大麻抽出物ならびにその調製方法および使用方法
JP2017535539A (ja) * 2014-10-21 2017-11-30 ユナイテッド カナビス コーポレイション 大麻抽出物ならびにその調製方法および使用方法
US10555928B2 (en) 2014-10-21 2020-02-11 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US11291650B2 (en) 2014-10-21 2022-04-05 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
US12582630B2 (en) 2014-10-21 2026-03-24 Nascent Pharma Llc Cannabis extracts and methods of preparing and using same
US20170165224A1 (en) * 2015-12-09 2017-06-15 Mark KWIECINSKI Compositions for improving safety of pharmacological formulations
US9789081B2 (en) * 2015-12-09 2017-10-17 Mark KWIECINSKI Compositions for improving safety of pharmacological formulations
US10555906B2 (en) 2016-02-11 2020-02-11 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
WO2017137992A1 (en) * 2016-02-11 2017-08-17 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US11654111B2 (en) 2016-02-11 2023-05-23 Satipharm Ag Oral solid cannabinoid formulations, methods for producing and using thereof
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11241413B2 (en) 2019-04-17 2022-02-08 Nordiccan A/S Cannabinoid lozenge formulation

Also Published As

Publication number Publication date
IN2014DN09718A (https=) 2015-07-31
AU2013260246A2 (en) 2014-11-27
EP2846768B1 (en) 2016-08-10
US20160367522A1 (en) 2016-12-22
CN104363890B (zh) 2018-01-26
ES2600465T3 (es) 2017-02-09
JP2015521175A (ja) 2015-07-27
AU2013260246A1 (en) 2014-11-27
CA2872689A1 (en) 2013-11-14
AU2013260246B2 (en) 2018-01-25
EP2846768A1 (en) 2015-03-18
CA2872689C (en) 2021-03-30
US20150132400A1 (en) 2015-05-14
CN104363890A (zh) 2015-02-18
US9555019B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
US9555019B2 (en) Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
US12350371B2 (en) Immediate release formulations of cannabinoids
US10245237B2 (en) Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
CA2929325C (en) Compressed tablet containing .delta.9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
CN113939283A (zh) 大麻素制剂
JP2010503664A (ja) 水不溶性医薬活性物質の舌下、頬若しくは経口投与のための医薬投薬単位

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13724009

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
REEP Request for entry into the european phase

Ref document number: 2013724009

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013724009

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2872689

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015511392

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14399487

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013260246

Country of ref document: AU

Date of ref document: 20130503

Kind code of ref document: A